Cmpx stock forecast.

The above table shows the analyst CMPX forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$1.77

Cmpx stock forecast. Things To Know About Cmpx stock forecast.

KNTE Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Kinnate Biopharma in the last 3 months. The average price target is $2.70 with a high forecast of $4.00 and a low forecast of $1.50. The average price target represents a 20.00% change from the last price of $2.25.Learn more about Compass Therapeutics, Inc.'s (CMPX) dividend history, ex-dividend date, and yield. Zacks.com Our Research, Your SuccessA convolutional neural network (CNN) is applied to forecast stock price changes in the Chinese stock market. We use 27 technical indicators and 5 original price series as benchmark models and ...Tutorial video for Capsim business simulation. In this video, I take you on a step-by-step demonstration on how you can do Forecasting, Marketing, and Produc...Comprehensive selection of real-time charts, which plot movements in the forex, futures and stock markets, with quotes updated continuously throughout the trading day.

CMPX Overview Stock Screener Earnings Calendar Sectors Nasdaq | CMPX U.S.: Nasdaq Compass Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Oct 13, 2023 4:38...To get a sense of who is truly in control of Compass Therapeutics, Inc. (NASDAQ:CMPX), it is important to understand the ownership structure of the business. The group holding the most number of ...Compass Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction. ... CMPX Related stocks. Symbol 3M %Chg ; CMPX +4.67% : Compass Therapeutics ...

Safe & Green Development Corp. $1.95. -0.70. -26.42%. COMP | A complete NASDAQ Composite Index index overview by MarketWatch. View stock market news, stock market data and trading information.

CMPX: Compass Therapeutics, Inc. - Price and Consensus Chart. Get the latest Price and Consensus Chart for Compass Therapeutics, Inc. from Zacks Investment ResearchStock Price Forecast. According to 4 stock analysts, the average 12-month stock price forecast for CMPX stock stock is $9.33, which predicts an increase of 442.44%. The lowest target is $8.00 and the highest is $10.3. On average, analysts rate CMPX stock stock as a strong buy.Find the latest Capital Power Corporation (CPX.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W ...The average one-year price target for CMPX / Compass Therapeutics Inc is $9.35. The forecasts range from a low of $8.08 to a high of $11.55. A stock’s price target is the price at which analysts consider it fairly valued with respect to …

Compass Therapeutics Inc (CMPX) stock price, GURU trades, performance, financial stability, valuations, and filing info from GuruFocus. 🚀 Enjoy a 7-Day Free Trial Thru Dec 01, 2023! Sign Up

Compass Therapeutics (NASDAQ: CMPX) is owned by 70.34% institutional shareholders, 11.41% Compass Therapeutics insiders, and 18.26% retail investors. Thomas J. Schuetz is the largest individual Compass Therapeutics shareholder, owning 5.98M shares representing 4.69% of the company.

c1968 kd 99121 57/64 bolt type lock 1k-compx stock locksThe Compx International, Inc. - Class A stock forecast is 40.29786370896 USD for 2024 November 25, Monday; and 148.757 USD for 2028 November 25, Saturday with technical analysis. Compx International, Inc. - Class A (CIX) stock price prediction is 40.29786370896 USD.Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...Our goal is to do fundamental research, invent new technology, and create frameworks for stock forecast.Analyst Forecast. According to 4 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 452.07% from the latest price.

Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...Look out for CMPX's next earnings release expected on November 08, 2023. For the next earning release, we expect the company to report earnings of -$0.11 per share, reflecting a year-over-year ...Nov 24, 2023 · View Compass Therapeutics, Inc CMPX investment & stock information. Get the latest Compass Therapeutics, Inc CMPX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 18 brokerages have issued 1-year price objectives for ChargePoint's shares. Their CHPT share price targets range from $2.00 to $17.00. On average, they expect the company's share price to reach $9.13 in the next year. This suggests a possible upside of 380.1% from the stock's current price.Compx International Inc: A High-Performing Stock with a GF Score of 93. GF Score analysis. Find the latest CompX International Inc. (CIX) stock quote, history, news and other vital information to ...Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.APRE Stock 12 Months Forecast. $15.00. (300.00% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Aprea Therapeutics in the last 3 months. The average price target is $15.00 with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 300.00% change from the last price of $3.75.

If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.Greenlane Holdings, Inc. (NASDAQ:GNLN) released its earnings results on Monday, November, 15th. The company reported ($46.00) earnings per share for the quarter, missing the consensus estimate of ($14.00) by $32.00. The company had revenue of $41.31 million for the quarter, compared to analyst estimates of $40.31 million.Get The Latest TVE Stock Analysis, Price Target, Dividend Info, and Headlines at MarketBeat. ... View our TVE earnings forecast. How were Tamarack Valley Energy's earnings last quarter? Tamarack Valley Energy Ltd (TSE:TVE) issued its quarterly earnings data on Thursday, October, 26th. The company reported $0.02 EPS …As per the forecast and algorithmic analysis, CMPX stock price can be as low as $1.71 which is 1.04% higher than the current price in the next 2 weeks. This prediction may vary from other time period filters for CMPX stock. The consensus price target of analysts on Wall Street is $2.50, which implies an increase of 83.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.50 and $2.50 respectively. As a result, VGZ is trading at a discount of -495.24% off the target high and -495.24% off the low.Get actionable alerts from top Wall Street Analysts. Find out before anyone else which stock is going to shoot up. Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. Get the latest Apexigen APGN Stock forecast and financial predictions, including earnings and sales forecast, on TipRanks.com.News Ideas Financials Technicals Forecast CMPX chart Today 2.59% 5 days 2.06% 1 month 3.66% 6 months −31.25% Year to date −61.10% 1 year −34.44% 5 years −76.71% All time −76.71% Key stats Market capitalization 252.37M USD Dividends yield (FY) — Price to earnings Ratio (TTM) — Basic EPS (TTM) −0.37 USD Net income −39.225M USD Revenue — Shares float

Stock Quote & Chart; Historic Price Lookup; Investment Calculator; IR Resources. Investor FAQs; Email Alerts; Contact IR; Careers; Press Releases; Cingulate In the News; back to top. close search window. Search: search submit button. Home. About Us. Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new …

Compass Therapeutics, Inc. Common Stock (CMPX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Leader in personal finance news and business forecasting. Get trusted advice on investing, retirement, taxes, saving, real estate, cars, college, insurance.According to the issued ratings of 4 analysts in the last year, the consensus rating for Catalyst Pharmaceuticals stock is Buy based on the current 4 buy ratings for CPRX. The average twelve-month price prediction for Catalyst Pharmaceuticals is $24.75 with a high price target of $27.00 and a low price target of $24.00. CMPX stock forecast Our latest prediction for Compass Therapeutics Inc's stock price was made on the March 15, 2023 when the stock price was at 3.56$. In the short term (2weeks), CMPX's stock price should underperform the market by -2.94%. During that period the price should oscillate between -8.72% and +5.46%.5 brokers have issued 12 month target prices for Zura Bio's stock. Their ZURA share price targets range from $10.00 to $22.00. On average, they predict the company's stock price to reach $16.60 in the next twelve months. This suggests a possible upside of 257.0% from the stock's current price.View the latest CMPX earnings date, analysts forecasts, earnings history, and conference call transcripts. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. QQQ 389.94. ... Stock Ideas and …Aeterna Zentaris (TSE:AEZS) Forecast: Is this specialty biopharmaceutical company a good stock to buy? Find out the latest analysis, ratings, and price targets from TipRanks, the leading platform for financial insights.Future criteria checks 0/6. Compass Therapeutics is forecast to grow earnings and revenue by 21.6% and 76.7% per annum respectively while EPS is expected to grow by 25.3% per annum.CMPX stock forecast Our latest prediction for Compass Therapeutics Inc's stock price was made on the March 15, 2023 when the stock price was at 3.56$. In the short term (2weeks), CMPX's stock price should underperform the market by -2.94%. During that period the price should oscillate between -8.72% and +5.46%. Stock Price Forecast. According to 4 stock analysts, the average 12-month stock price forecast for CMPX stock stock is $9.33, which predicts an increase …Find the latest Capital Power Corporation (CPX.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W ...Compass Therapeutics Inc. (CMPX) stock is trading at $3.95 as of 12:48 PM on Tuesday, Jan 31, an increase of $0.10, or 2.6% from the previous closing price of $3.85. The stock has traded between $3.88 and $4.13 so far today. Volume today is less active than usual.10% most volatile stocks in GB Market. 12.0%. 10% least volatile stocks in GB Market. 2.6%. Stable Share Price: CPX is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 12% a week. Volatility Over Time: CPX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.

Jul 11, 2023 · CMPX Stock Forecast 2023. Compass Therapeutics boasts a robust drug pipeline, which explains why analysts are bullish on the stock. The Phase 2 and Phase 3 studies for cancer drug CTX-009 extend into H2 2023, at which time the company plans to initiate a Phase 1 study for its CTX-8371 drug also for cancer after filing an Investigational New Drug Application (IND) earlier in 2023. Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...A high-level overview of Compass Therapeutics, Inc. (CMPX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Instagram:https://instagram. forex 100best veteran mortgage lendershow to invest dollar5000gilead stock quote CPX Earnings Date and Information. Capital Power last announced its quarterly earnings results on November 1st, 2023. The reported C$2.26 EPS for the quarter, beating analysts' consensus estimates of C$1.37 by C$0.89. The company had revenue of C$1.15 billion for the quarter. Capital Power has generated C$4.40 earnings per share … shein conecta modahandr block protection In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.Nov 24, 2023 · View Compass Therapeutics, Inc CMPX investment & stock information. Get the latest Compass Therapeutics, Inc CMPX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. soxl stock forecast Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Get the latest news and real-time alerts from Compass Therapeutics, Inc. (CMPX) stock at Seeking Alpha. ... CMPX Compass Therapeutics, Inc. Latest News. Follow $1.93 0.00 (0.00%) ...Jul 11, 2023 · CMPX Stock Forecast 2023. Compass Therapeutics boasts a robust drug pipeline, which explains why analysts are bullish on the stock. The Phase 2 and Phase 3 studies for cancer drug CTX-009 extend into H2 2023, at which time the company plans to initiate a Phase 1 study for its CTX-8371 drug also for cancer after filing an Investigational New Drug Application (IND) earlier in 2023.